Physician profile
John E Marcellus
NPI 1972647352
$11,402.73
in general payments reported to CMS, 2019-2025
27 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $711 · 2021: $990 · 2022: $1,481 · 2023: $3,832 · 2024: $2,007 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,450 · Consulting Fee: $1,800 · Travel and Lodging: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,449.84 |
| Consulting Fee | $1,800.00 |
| Travel and Lodging | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $3,058.62 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,436.24 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,092.24 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $875.31 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $852.59 | 2019-2025 | Invega Sustenna, Invega |
| Abbvie INC. | $602.32 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $595.22 | 2019-2024 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $559.80 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $530.24 | 2020-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $359.08 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $278.37 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $149.79 | 2025 | Cobenfy |
| Neos Therapeutics, Lp | $147.21 | 2023-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $146.67 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $120.90 | 2021-2023 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $97.60 | 2024-2025 | Auvelity |
| Shire North American Group INC | $87.11 | 2019 | |
| Bausch Health US, LLC | $69.34 | 2020-2025 | Wellbutrin, Aplenzin |
| Indivior INC. | $58.35 | 2022 | |
| Vanda Pharmaceuticals INC. | $50.78 | 2019-2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $50.57 | 2019-2022 | |
| Almatica Pharma LLC | $47.99 | 2024 | Loreev Xr |
| Eisai INC. | $46.50 | 2020-2021 | |
| Tris Pharma INC | $39.65 | 2024 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $22.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.53 | 2020 | |
| Allergan, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marcellus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.